You are being redirected because this document is part of your ASTM Compass® subscription.
    This document is part of your ASTM Compass® subscription.

    Volume 20, Issue 2 (April 1975)

    Fatal Anaphylaxis After Intravenous Iron Dextran

    (Received 10 June 1974; accepted 6 August 1974)

    Published Online: 1975


      Format Pages Price  
    PDF (756K) 8 $25   ADD TO CART

    Cite this document

    X Add email address send
      .RIS For RefWorks, EndNote, ProCite, Reference Manager, Zoteo, and many others.   .DOCX For Microsoft Word


    Iron dextran (Imferon®) is a complex of ferric iron and dextran widely used for the treatment of iron deficiency anemia. It became commercially available in the United States in 1957. Since that time the intramuscular administration of iron dextran has been considered a relatively safe manner of administering iron to patients unable to tolerate oral iron therapy. However, untoward side effects have been reported. The most common of these are discomfort or staining of the skin at the injection site. The more disturbing reactions, however, appear to be allergic in nature and include lymphadenopathy, fever, urticaria, angioneurotic edema, arthralgias, and transient shocklike conditions [1–5]. Recently four cases of fatal anaphylaxis following intramuscular injection of iron dextran have been reported [6,7].

    Author Information:

    Zipf, RE
    Pathologist, Riverside Hospital Laboratories, Columbus, Ohio

    Stock #: JFS10279J


    DOI: 10.1520/JFS10279J

    Title Fatal Anaphylaxis After Intravenous Iron Dextran
    Symposium ,
    Committee E30